Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $89.74. The business has a fifty day moving average of $83.79 and a 200-day moving average of $74.21.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $105.00. Chris Schott has given his Buy rating due to a ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.95% on an annualized basis producing an average annual return of 12.29%. Currently, Gilead Sciences has a market ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (LSE:0QYQ) from Buy to Hold. As of October 22, 2024, the average one-year price target for Gilead ...

In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $95.00. Tyler Van Buren’s rating is ...

Gilead Sciences (GILD) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $2.29 per share a year ago.

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost ...

MISSISSAUGA — Gilead Sciences Canada, Inc. (Gilead Canada) announced that Paul Petrelli joined the organization as Vice President and General Manager. In his new role, Petrelli will be ...

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen ...

Gilead Sciences (GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from its COVID revenues and spurring investor anticipation for new products ...